AU Patent

AU2010234562B2 — Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Assigned to Taiho Pharmaceutical Co Ltd · Expires 2016-05-12 · 10y expired

What this patent protects

Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.

USPTO Abstract

Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010234562B2
Jurisdiction
AU
Classification
—
Expires
2016-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Taiho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.